News & Updates

Show Multimedia Only
Lecanemab moderately slows decline in early AD, associated with AEs Lecanemab moderately slows decline in early AD, associated with AEs

Lecanemab moderately slows decline in early AD, associated with AEs

06 Dec 2022 byNatalia Reoutova

Lecanemab reduces brain amyloid burden and offers moderate slowing of cognitive decline in early Alzheimer’s disease (AD), but is associated with adverse events (AEs), according to the results of the phase III, double-blind, placebo-controlled CLARITY AD trial, presented at the 15th Clinical Trials on Alzheimer’s Disease (CTAD 2022) conference.

06 Dec 2022
Group CBT may help improve emotion regulation in adults with autism

Group CBT may help improve emotion regulation in adults with autism

04 Dec 2022

Among adults with autism spectrum disorder (ASD), group-based cognitive behavioural therapy (CBT) appears to yield modest improvements in emotion regulation, a recent study has found.

04 Dec 2022
ADHD medication use carries no excess risk of cardiovascular diseases

ADHD medication use carries no excess risk of cardiovascular diseases

02 Dec 2022

Users of attention-deficit/hyperactivity disorder (ADHD) medications across age groups do not appear to be at increased risk of cardiovascular diseases (CVDs), although a modest risk increase of cardiac arrest or tachyarrhythmias could not be ruled out, according to the results of a meta-analysis.

02 Dec 2022